Parabilis Medicines Announces Pricing of Upsized Initial Public Offering

Parabilis Medicines, a clinical-stage biopharmaceutical company, priced its IPO at $20 per share for 33.5 million shares, expected to raise $670 million in gross proceeds. The company will also receive approximately $75 million from a concurrent private placement with Regeneron Pharmaceuticals at $18 per share. Trading on Nasdaq under ticker PBLS is expected to begin June 10, 2026.